VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viridian Therapeutics, Inc.\DE
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$20.80+1.77 (+9.30%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Viridian Therapeutics, Inc.\DE statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Market Cap | $2.36B | $197.05M |
| Enterprise Value | $1.37B | $106.56M |
| PS Ratio | 33.13 | 3.93 |
| PB Ratio | 3.56 | 2.14 |
| P/TBV Ratio | 3.61 | 2.46 |
Enterprise value
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| EV / Sales | 19.33 | 2.69 |
Income (trailing twelve months)
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Revenue | $71.13M | $57.94M |
| Operating Income | -$405.20M | -$21.44M |
| Net Income | -$386.97M | -$22.46M |
| EBITDA | -$404.73M | -$16.91M |
Margins
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Operating Margin | -569.7% | -44.5% |
| Profit Margin | -544.1% | -39.2% |
| EBITDA Margin | -569.0% | -31.3% |
| FCF Margin | -471.0% | -8.85% |
Returns
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Return on Equity (ROE) | -65.7% | -53.1% |
| Return on Assets (ROA) | -46.1% | -41.0% |
| Return on Capital Employed (ROCE) | -39.2% | -37.8% |
Growth
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 23220.3% | 6.01% |
| Revenue Growth (3Y CAGR) | 241.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 132.2% | 6.42% |
Balance sheet
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $981.50M | $62.42M |
| Net Cash (Debt) | $981.50M | $15.68M |
| Net Cash Per Share | $8.66 | $0.65 |
| Equity (Book Value) | $662.10M | $48.79M |
| Book Value Per Share | $5.84 | $1.36 |
| Tangible Book Value | $652.10M | $23.06M |
| Working Capital | $1.02B | $75.77M |
Financial position
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Current Ratio | 16.95 | 3.30 |
| Quick Ratio | 15.39 | 2.39 |
| Interest Coverage | -25.96 | -7.12 |
Cash flow (trailing twelve months)
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Operating Cash Flow | -$333.34M | -$12.35M |
| Capital Expenditures | -$1.70M | -$1.06M |
| Free Cash Flow | -$335.04M | -$20.28M |
| FCF Per Share | -$2.96 | -$0.41 |
Efficiency
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Asset Turnover | 0.08 | 0.38 |
| Revenue Per Employee | $282.25K | $398.96K |
| Profits Per Employee | -$1.54M | -$732.08K |
| Employee Count | 252 | 73 |
Dividends and yields
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Earnings Yield | -16.4% | -21.2% |
| FCF Yield | -14.2% | -7.64% |
| Buyback Yield | -2.47% | -0.58% |
| Shareholder Yield | -2.47% | 0.00% |
Shares
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Shares Outstanding | 113,292,000 | 59,128,900 |
| Shares Change (QoQ) | 10.5% | 0.54% |
| Float | 88,621,500 | 48,744,500 |
| Shares Held by Insiders | 21.8% | 11.8% |
| Shares Held by Institutions | 120.1% | 59.4% |
Scores
| Measure | Viridian Therapeutics, Inc.\DE | Industry median |
|---|---|---|
| Altman Z-Score | 1.20 | 0.10 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Viridian Therapeutics, Inc.\DE's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.